Encapsulating peritoneal sclerosis: case series from a university center
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Encapsulating peritoneal sclerosis (EPS) is an often-fatal complication of long-term peritoneal dialysis (PD). We here report the clinical features of EPS in Korean PD patients from a single university center. Methods: The data were collected retrospectively from 606 PD patients at Kyungpook National University Hospital, between August 2001 and August 2011. The diagnosis of EPS was based on clinical signs and symptoms, and confirmed by radiological findings. Results: Eight patients (1.3%, four males) were diagnosed with EPS. The mean age of the patients was 48.5 years (range, 33 to 65). The mean duration of PD was 111.8months (range, 23 to 186). All patients except for one had three or more episodes of peritonitis. Seven patients were diagnosed with EPS after stopping PD, and only one stayed on PD after initial diagnosis and treatment. Total parenteral nutrition and corticosteroids, in addition to tamoxifen therapy, were used to treat most of the patients, and one patient underwent surgery (adhesiolysis). The overall mortality rate was 50%. Conclusions: EPS is a serious, life-threatening complication in patients on longterm PD. To reduce the incidence and mortality rate of EPS, careful monitoring and early diagnosis is needed.
Abstract
Background/Aims: Encapsulating peritoneal sclerosis (EPS) is an often-fatal complication of long-term peritoneal dialysis (PD). We here report the clinical features of EPS in Korean PD patients from a single university center. Methods: The data were collected retrospectively from 606 PD patients at Kyungpook National University Hospital, between August 2001 and August 2011. The diagnosis of EPS was based on clinical signs and symptoms, and confirmed by radiological findings. Results: Eight patients (1.3%, four males) were diagnosed with EPS. The mean age of the patients was 48.5 years (range, 33 to 65). The mean duration of PD was 111.8months (range, 23 to 186). All patients except for one had three or more episodes of peritonitis. Seven patients were diagnosed with EPS after stopping PD, and only one stayed on PD after initial diagnosis and treatment. Total parenteral nutrition and corticosteroids, in addition to tamoxifen therapy, were used to treat most of the patients, and one patient underwent surgery (adhesiolysis). The overall mortality rate was 50%. Conclusions: EPS is a serious, life-threatening complication in patients on longterm PD. To reduce the incidence and mortality rate of EPS, careful monitoring and early diagnosis is needed.
참고문헌 (28)
- Brown EA, "Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD", Perit Dial Int, 29, pp.595~600 (2009)
- Rigby RJ, "Sclerosing peritonitis: the experience in Australia", Nephrol Dial Transplant, 13, pp.154~159 (1998)
- Kawanishi H, "Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study", Am J Kidney Dis, 44, pp.729~737 (2004)
- Johnson DW, "Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes", Kidney Int, 77, pp.904~912 (2010)
- Kawaguchi Y, "Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment: International Society for Peritoneal Dialysis Ad Hoc Committee on ultrafiltration management in peritoneal dialysis", Perit Dial Int, 20(4), pp.43~55 (2000)
- Kawanishi H, "Successful surgical management of encapsulating peritoneal sclerosis", Perit Dial Int, 25(4), pp.39~47 (2005)
- Ti JP, "Imaging features of encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients", AJR Am J Roentgenol, 195, pp.50~54 (2010)
- Tarzi RM, "Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis", Clin J Am Soc Nephrol, 3, pp.1702~1710 (2008)
- Korte MR, "Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study", Perit Dial Int, 31, pp.269~278 (2011)
- Lee HY, "Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea", Nephrology, 8, pp.33~39 (2003)
- Summers AM, "Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure", Kidney Int, 68, pp.2381~2388 (2005)
- Brown MC, "Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study", Clin J Am Soc Nephrol, 4, pp.1222~1229 (2009)
- Kawanishi H, "Epidemiology of encapsulating peritoneal sclerosis in Japan", Perit Dial Int, 25(4), pp.14~18 (2005)
- Chin AI, "Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis", Am J Kidney Dis, 47, pp.697~712 (2006)
- Afthentopoulos IE, "Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature", Adv Ren Replace Ther, 5, pp.157~167 (1998)
- Sawai T, "Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads", Infect Immun, 65, pp.466~471 (1997)
- Kocianova S, "Key role of polygamma- DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis", J Clin Invest, 115, pp.688~694 (2005)
- Moriishi M, "Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients", Adv Perit Dial, 22, pp.24~28 (2006)
- Habib AM, "Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription", Nephrol Dial Transplant, 25, pp.1633~1638 (2010)
- Dobbie JW, "Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis", Perit Dial Int, 12, pp.14~27 (1992)
- Kyuden Y, "Tgfbeta1 induced by high glucose is controlled by angiotensin- converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells", Perit Dial Int, 25, pp.483~491 (2005)
- Noh H, "Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species", Perit Dial Int, 25, pp.38~47 (2005)
- Korte MR, "Encapsulating peritoneal sclerosis: the state of affairs", Nat Rev Nephrol, 7, pp.528~538 (2011)
- Kuriyama S, "Corticosteroid therapy in encapsulating peritoneal sclerosis", Nephrol Dial Transplant, 16, pp.1304~1305 (2001)
- Eltoum MA, "Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen", Perit Dial Int, 26, pp.203~206 (2006)
- Lafrance JP, "Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy", Am J Kidney Dis, 51, pp.7~10 (2008)
- Balasubramaniam G, "The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis", Nephrol Dial Transplant, 24, pp.3209~3215 (2009)
- Kawanishi H, "Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study", Perit Dial Int, 21(3), pp.67~71 (2001)